All Deals
November 13, 2025 - Deals
Vend Park Secures $17.5 Million In Series A Funding Led By Blue Heron Capital
Vend Park, a Boston-based parking operations platform, raised $17.5 million in Series A funding led by Blue Heron Capital, with participation from Nuveen’s Real Asset Ventures, Communitas Capital, John McMahon, and follow-on investments from Derive Ventures, Floating Point Capital, PagsGroup, Crossbeam, and others. Led by CEO Michael Miele, Vend Park combines AI technology with an operations team to help commercial real estate owners manage and monetize parking across office towers, mixed-use properties, healthcare facilities, hotels, university campuses, event venues, and airports. The company plans to use the new funding to accelerate expansion into major U.S. markets, advance its AI-powered product roadmap, and grow its teams in sales, engineering, and customer success, serving clients including Nuveen, Jamestown, Federal Realty, and Harwood International.
FOUNDER: Michael Miele
INVESTORS: Blue Heron Capital, Nuveen’s Real Asset Ventures, Communitas Capital, John McMahon, Derive Ventures, Floating Point Capital, PagsGroup & Crossbeam
ROUND: Series A
AMOUNT: $17,500,000
HQ: #Boston #Massachusetts
#VentureCapital #VendPark #MichaelMiele #BlueHeronCapital #NuveenRealAssetVentures #CommunitasCapital #JohnMcMahon #DeriveVentures #FloatingPointCapital #PagsGroup #Crossbeam #TradedVC
More Deals
View All
Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts.
FOUNDERS: Ben Lamm & George Church
TARGET VALUATION: $23,000,000,000
HQ: Dallas, Texas
#VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC